Woodline Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Woodline Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.9M	Buy	125,899 +240	+0.2%	+$115K	0.25%	94
2025 Q4	$73.2M	Buy	125,659 +21,812	+21%	+$11.1M	0.28%	78
2025 Q3	$47.6M	Sell	103,847 -55,776	-35%	-$20.8M	0.22%	121
2025 Q2	$48.3M	Sell	159,623 -157,810	-50%	-$47M	0.26%	102
2025 Q1	$105M	Buy	317,433 +8,316	+3%	+$2.73M	0.68%	15
2024 Q4	$95.4M	Buy	309,117 +162,027	+110%	+$45.6M	0.64%	16
2024 Q3	$31.2M	Buy	147,090 +8,781	+6%	+$2.25M	0.26%	124
2024 Q2	$38.7M	Buy	138,309 +118,609	+602%	+$28.2M	0.37%	74
2024 Q1	$5.26M	Buy	+19,700	New	+$4.64M	0.05%	352
2023 Q2	–	Sell	-12,358	Closed	-$2.99M	–	707
2023 Q1	$2.99M	Buy	12,358 +10,779	+683%	+$2.94M	0.04%	372
2022 Q4	$458K	Sell	1,579 -16,544	-91%	-$1.62M	0.01%	607
2022 Q3	$1.18M	Sell	18,123 -64,053	-78%	-$4.45M	0.02%	524
2022 Q2	$5.88M	Buy	+82,176	New	+$6.04M	0.09%	238

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners's MDGL Position: Q1 2026 in Review

Woodline Partners increased its Madrigal Pharmaceuticals (MDGL) stake by 0.19% in Q1 2026, buying an estimated $115K and bringing the position to 125,899 shares worth $65.9M. The position accounts for 0.25% of the portfolio, ranked #94.

Woodline Partners first reported a position in MDGL in Q2 2022 and has held it in 13 quarters since. The position peaked at $105M in Q1 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Woodline Partners held 125,899 shares of Madrigal Pharmaceuticals worth $65.9M as of Q1 2026.
Woodline Partners bought 240 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $115K.
Madrigal Pharmaceuticals made up 0.25% of Woodline Partners's portfolio in Q1 2026, its #94 holding.
Woodline Partners first reported a position in Madrigal Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
Woodline Partners's Madrigal Pharmaceuticals position peaked at $105M in Q1 2025.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.